News for Trillium Therapeutics Inc. (TRIL.TO)

Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors London, UK – July 10, 2024 – Quell...

Aug 23, 2021 / 02:00PM GMTOperator Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to discuss proposed acquisition of Trillium Therapeutic

The Global Hematuria Treatment Market Size was valued at USD 933.2 million in 2021 and the worldwide hematuria treatment market size is expected to reach...

BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel...

Assuming an upward rerating, PFE could hit our price target of $55.79, suggesting 27.40% upside potential from current levels. Click here to read our analysis.

NEW YORK and SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical...

Read Trillium Therapeutics (TSE:TRIL) Trading Up 0.5% at ETF Daily News

Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in...

Doxorubicin Market is expected to reach US$ 1,983.40 million by 2028 from US$ 1,390.64 million in 2022. It is estimated to grow at a CAGR of 6.1% from 2022...

/PRNewswire/ -- Research Dive has added a new report to its offering titled, "Nephrology Drugs Market by Type (ACE Inhibitor, Calcium Channel Blocker,...

By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public.

By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public.

GuruFocus Article or News written by insider and the topic is about:

GuruFocus Article or News written by insider and the topic is about:

GuruFocus Article or News written by insider and the topic is about:

Gainers Trillium Therapeutics Inc. (NASDAQ:TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pf...

GuruFocus Article or News written by insider and the topic is about:

GuruFocus Article or News written by insider and the topic is about:

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au...